Literature DB >> 16952371

Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.

Holger Steuber1, Matthias Zentgraf, Christof Gerlach, Christoph A Sotriffer, Andreas Heine, Gerhard Klebe.   

Abstract

In structure-based drug design, accurate crystal structure determination of protein-ligand complexes is of utmost importance in order to elucidate the binding characteristics of a putative lead to a given target. It is the starting point for further design hypotheses to predict novel leads with improved properties. Often, crystal structure determination is regarded as ultimate proof for ligand binding providing detailed insight into the specific binding mode of the ligand to the protein. This widely accepted practise relies on the assumption that the crystal structure of a given protein-ligand complex is unique and independent of the protocol applied to produce the crystals. We present two examples indicating that this assumption is not generally given, even though the composition of the mother liquid for crystallisation was kept unchanged: Multiple crystal structure determinations of aldose reductase complexes obtained under varying crystallisation protocols concerning soaking and crystallisation exposure times were performed resulting in a total of 17 complete data sets and ten refined crystal structures, eight in complex with zopolrestat and two complexed with tolrestat. In the first example, a flip of a peptide bond is observed, obviously depending on the crystallisation protocol with respect to soaking and co-crystallisation conditions. This peptide flip is accompanied by a rupture of an H-bond formed to the bound ligand zopolrestat. The indicated enhanced local mobility of the complex is in agreement with the results of molecular dynamics simulations. As a second example, the aldose reductase-tolrestat complex is studied. Unexpectedly, two structures could be obtained: one with one, and a second with four inhibitor molecules bound to the protein. They are located in and near the binding pocket facilitated by crystal packing effects. Accommodation of the four ligand molecules is accompanied by pronounced shifts concerning two helices interacting with the additional ligands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952371     DOI: 10.1016/j.jmb.2006.08.011

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  23 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

Review 2.  Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.

Authors:  I M Kapetanovic
Journal:  Chem Biol Interact       Date:  2006-12-16       Impact factor: 5.192

3.  Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

Authors:  Mahmoud A Al-Sha'er; Mohammad A Khanfar; Mutasem O Taha
Journal:  J Mol Model       Date:  2014-01-28       Impact factor: 1.810

4.  The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.

Authors:  Mutasem O Taha; Maha Habash; Mohammad A Khanfar
Journal:  J Comput Aided Mol Des       Date:  2014-03-08       Impact factor: 3.686

5.  Multivariate Analyses of Quality Metrics for Crystal Structures in the PDB Archive.

Authors:  Chenghua Shao; Huanwang Yang; John D Westbrook; Jasmine Y Young; Christine Zardecki; Stephen K Burley
Journal:  Structure       Date:  2017-02-16       Impact factor: 5.006

6.  BP-Dock: a flexible docking scheme for exploring protein-ligand interactions based on unbound structures.

Authors:  Ashini Bolia; Z Nevin Gerek; S Banu Ozkan
Journal:  J Chem Inf Model       Date:  2014-03-04       Impact factor: 4.956

7.  AMP-activated protein kinase undergoes nucleotide-dependent conformational changes.

Authors:  Lei Chen; Jue Wang; Yuan-Yuan Zhang; S Frank Yan; Dietbert Neumann; Uwe Schlattner; Zhi-Xin Wang; Jia-Wei Wu
Journal:  Nat Struct Mol Biol       Date:  2012-06-03       Impact factor: 15.369

8.  Target flexibility: an emerging consideration in drug discovery and design.

Authors:  Pietro Cozzini; Glen E Kellogg; Francesca Spyrakis; Donald J Abraham; Gabriele Costantino; Andrew Emerson; Francesca Fanelli; Holger Gohlke; Leslie A Kuhn; Garrett M Morris; Modesto Orozco; Thelma A Pertinhez; Menico Rizzi; Christoph A Sotriffer
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

9.  Path-integral method for predicting relative binding affinities of protein-ligand complexes.

Authors:  Chandrika Mulakala; Yiannis N Kaznessis
Journal:  J Am Chem Soc       Date:  2009-04-01       Impact factor: 15.419

10.  Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

Authors:  Malkhey Verma; Hans-Joerg Martin; Wahajul Haq; Timothy R O'Connor; Edmund Maser; Ganesaratnam K Balendiran
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.